Skip to main content
. 2022 Feb 18;31:09636897221077921. doi: 10.1177/09636897221077921

Figure 1.

Figure 1.

Celecoxib suppresses the activation of AKT and ERK signal pathways which activated by MLN4924, and enhances the suppression of growth in UC cells by MLN4924 (A–B) T24 and 5637 cells were incubated with various concentration of MLN4924 (0, 0.1, 0.3, 1 μM) with or without celecoxib (60 μM) for 24 h, followed by Western blotting using antibodies against p-AKT (S473), AKT, ERK, and p-ERK. β-actin was used as a loading control. (C–D) A total of 4000 T24 cells and 6000 5637 cells were seeded in triplicate in 96-well plates and treated with various concentrations of celecoxib, MLN4924, or the combination of MLN4924 and celecoxib (50 μM) for 48 h, followed by the CCK-8 assay (mean ± SEM, n = 3). (E) CI-fraction affected plot of the MLN4924/celecoxib combination in T24 and 5637 cells assessed with Compusyn Software (Fa, corresponding to the fraction of cell viability, the synergistic effect was considered if CI < 1, and additive if CI = 1, antagonistic if CI > 1). UC: urothelial carcinoma; CCK-8: cell counting kit-8; SEM: standard error of the mean; CI: combination index. **0.005 < P < 0.01, ***P < 0.005.